• Unaudited total revenue of US$0.80m, up 41.1% on Q3 FY24
• Completion of Laitek acquisition, adding data migration and routing services
• Multiple new customer and distribution agreements signed, including Darwinist, Medica, Philips, Bayer, DMC, National Cancer Centre Japan and UltraRad

Enlitic Inc. (ASX: ENL) has released its Quarterly Activity Report and Appendix 4C for the three-month period ended 31 December 2024 (Q4 FY24). The company reported unaudited total revenue of US$0.80m, up 41.1% on Q3 FY24. Key highlights include the completion of the Laitek acquisition, which added data migration and routing services to Enlitic's offering, and the signing of multiple new customer and distribution agreements with Darwinist, Medica Group, Philips Healthcare, Bayer, DMC Healthcare, National Cancer Centre Japan and UltraRad. The company raised A$22.5m through a conditional placement and A$906k through a share purchase plan, which were used to fund the Laitek acquisition and provide working capital. Enlitic's open pipeline opportunity at 31 December 2024 was US$93.3m. The company expects to reach operational cashflow break-even by the end of 2025, with normalised costs expected to be substantially lower in FY25.

The company expects to reach operational cashflow break-even by the end of 2025.

Enlitic remains focused on providing the healthcare industry with AI-driven solutions to their data efficiency and interoperability challenges, while driving long-term growth for its shareholders. The company is prioritising the continued growth of migrations to its platform to drive revenue growth in FY25.